{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T07:12:32Z","timestamp":1771485152017,"version":"3.50.1"},"reference-count":142,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:00:00Z","timestamp":1771459200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Ovarian cancer (OC), particularly high-grade serous ovarian cancer (HGSOC), is among the most lethal gynecologic malignancies, with its therapeutic challenges primarily stemming from a distinctly immunosuppressive tumor immune microenvironment (TIME). Neoadjuvant chemotherapy (NACT) has emerged as a crucial treatment strategy for advanced ovarian cancer; nevertheless, its impact on the tumor microenvironment\u2014especially on tumor-infiltrating lymphocytes (TILs)\u2014is not yet fully understood. As central mediators of antitumor immune responses, the density, composition, and dynamic changes of TILs are strongly associated with chemotherapy response and patient prognosis. Notably, spatial omics studies further revealed that, after NACT, a subset of CD8+ T cells can be confined within \u201cmyelonets\u201d microdomains organized by myeloid cells, where interactions such as NECTIN2\u2013TIGIT impose spatial restriction and induce functional exhaustion of T cells, thereby compromising their effective tumor killing. This review aims to systematically summarize the baseline characteristics and heterogeneity of lymphoid- and myeloid-derived TILs in ovarian cancer, elucidate the mechanisms underlying immune remodeling induced by NACT and their complex relationships with clinical outcomes, and further discuss combination therapeutic strategies and biomarker development based on dynamic TIL changes to enhance the clinical application of precision immunotherapy.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1757366","type":"journal-article","created":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T06:41:26Z","timestamp":1771483286000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Neoadjuvant chemotherapy-induced immune remodeling in ovarian cancer: implications for TIL dynamics and combination immunotherapy"],"prefix":"10.3389","volume":"17","author":[{"given":"Wanting","family":"Zhu","sequence":"first","affiliation":[{"name":"Department of Gynecologic Oncology, Obstetrics and Gynecology Hospital of Fudan University, Shanghai Key Lab of Reproduction and Development, Shanghai Key Lab of Female Reproductive Endocrine Related Diseases","place":["Shanghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiajia","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Gynecologic Oncology, Obstetrics and Gynecology Hospital of Fudan University, Shanghai Key Lab of Reproduction and Development, Shanghai Key Lab of Female Reproductive Endocrine Related Diseases","place":["Shanghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yihua","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Pathology, Obstetrics and Gynecology Hospital of Fudan University","place":["Shanghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qianhan","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Gynecologic Oncology, Obstetrics and Gynecology Hospital of Fudan University, Shanghai Key Lab of Reproduction and Development, Shanghai Key Lab of Female Reproductive Endocrine Related Diseases","place":["Shanghai, China"]},{"name":"Department of Obstetrics and Gynecology, Beijing Anzhen Hospital, Capital Medical University","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yating","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Gynecologic Oncology, Obstetrics and Gynecology Hospital of Fudan University, Shanghai Key Lab of Reproduction and Development, Shanghai Key Lab of Female Reproductive Endocrine Related Diseases","place":["Shanghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengyang","family":"Xue","sequence":"additional","affiliation":[{"name":"Department of Gynecologic Oncology, Obstetrics and Gynecology Hospital of Fudan University, Shanghai Key Lab of Reproduction and Development, Shanghai Key Lab of Female Reproductive Endocrine Related Diseases","place":["Shanghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Gynecologic Oncology, Obstetrics and Gynecology Hospital of Fudan University, Shanghai Key Lab of Reproduction and Development, Shanghai Key Lab of Female Reproductive Endocrine Related Diseases","place":["Shanghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiuling","family":"Zhi","sequence":"additional","affiliation":[{"name":"Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Fudan University","place":["Shanghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liangqing","family":"Yao","sequence":"additional","affiliation":[{"name":"Department of Gynecologic Oncology, Obstetrics and Gynecology Hospital of Fudan University, Shanghai Key Lab of Reproduction and Development, Shanghai Key Lab of Female Reproductive Endocrine Related Diseases","place":["Shanghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mo","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Gynecologic Oncology, Obstetrics and Gynecology Hospital of Fudan University, Shanghai Key Lab of Reproduction and Development, Shanghai Key Lab of Female Reproductive Endocrine Related Diseases","place":["Shanghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32552-2","article-title":"Epithelial ovarian cancer","volume":"393","author":"Lheureux","year":"2019","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s12943-024-01967-3","article-title":"Drug resistance in ovarian cancer: from mechanism to clinical trial","volume":"23","author":"Wang","year":"2024","journal-title":"Mol Cancer"},{"key":"B3","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.ejcsup.2019.12.002","article-title":"Inflammation and immunity in ovarian cancer","volume":"15","author":"Salas-Benito","year":"2020","journal-title":"EJC Suppl"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1338119","article-title":"Editorial: Community series in novel insights into immunotherapy targeting tumor microenvironment in ovarian cancer: volume II","volume":"14","author":"Tong","year":"2023","journal-title":"Front Immunol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"4905","DOI":"10.1016\/j.cell.2024.06.013","article-title":"Neoadjuvant PARPi or chemotherapy in ovarian cancer informs targeting effector Treg cells for homologous-recombination-deficient tumors","volume":"187","author":"Luo","year":"2024","journal-title":"Cell"},{"key":"B6","doi-asserted-by":"publisher","first-page":"4344","DOI":"10.3390\/cancers14184344","article-title":"Prognostic and predictive role of tumor-infiltrating lymphocytes (TILs) in ovarian cancer","volume":"14","author":"Fanale","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1116\u201330","DOI":"10.1016\/j.trecan.2024.09.001","article-title":"Crosstalk of T cells within the ovarian cancer microenvironment","volume":"10","author":"Chap","year":"2024","journal-title":"Trends cancer"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1473969","article-title":"Tertiary lymphoid structures: exploring opportunities to improve immunotherapy in ovarian cancer","volume":"16","author":"Varghese","year":"2025","journal-title":"Front Immunol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"5332","DOI":"10.3390\/cancers14215332","article-title":"Tumor-infiltrating lymphocytes (TILs) in epithelial ovarian cancer: heterogeneity, prognostic impact, and relationship with immune checkpoints","volume":"14","author":"Hudry","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-020-0413-z","article-title":"Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors","volume":"17","author":"Galluzzi","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"2912","DOI":"10.3390\/cancers15112912","article-title":"Chemo-immunotherapy: A new trend in cancer treatment","volume":"15","author":"Sordo-Bahamonde","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B12","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1186\/s12943-025-02477-6","article-title":"Turning cold tumors into hot tumors to ignite immunotherapy","volume":"24","author":"Liu","year":"2025","journal-title":"Mol Cancer"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00342-9","article-title":"Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial","volume":"22","author":"Monk","year":"2021","journal-title":"Lancet Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00306","article-title":"Atezolizumab, bevacizumab, and chemotherapy for newly diagnosed stage III or IV ovarian cancer: placebo-controlled randomized phase III trial (IMagyn050\/GOG 3015\/ENGOT-OV39)","volume":"39","author":"Moore","year":"2021","journal-title":"J Clin Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.14919","article-title":"The prognostic value of tumor-infiltrating T lymphocytes in ovarian cancer","volume":"8","author":"Li","year":"2017","journal-title":"Oncotarget"},{"key":"B16","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.ccell.2022.03.008","article-title":"Ovarian cancer immunogenicity is governed by a narrow subset of progenitor tissue-resident memory T cells","volume":"40","author":"Anadon","year":"2022","journal-title":"Cancer Cell"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2022.04.008","article-title":"Tissue residency of memory CD8+ T cells matters in shaping immunogenicity of ovarian cancer","volume":"40","author":"Tsuji","year":"2022","journal-title":"Cancer Cell"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1935104","DOI":"10.1080\/2162402X.2021.1935104","article-title":"Prognostic image-based quantification of CD8CD103 T-cell subsets in high-grade serous ovarian cancer patients","volume":"10","author":"Paijens","year":"2021","journal-title":"Oncoimmunology"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2023.34.e48","article-title":"Th2 cells infiltrating high-grade serous ovarian cancer: a feature that may account for the poor prognosis","volume":"34","author":"Su","year":"2023","journal-title":"J Gynecol Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.35149","article-title":"B cells critical for outcome in high grade serous ovarian carcinoma","volume":"155","author":"Vledder","year":"2024","journal-title":"Int J Cancer"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-042718-041717","article-title":"Regulatory T cells and human disease","volume":"38","author":"Sakaguchi","year":"2020","journal-title":"Annu Rev Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1631226","article-title":"Immunosuppressive mechanisms and therapeutic targeting of regulatory T cells in ovarian cancer","volume":"16","author":"Li","year":"2025","journal-title":"Front Immunol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1186\/s12935-024-03525-9","article-title":"Th17 cell function in cancers: immunosuppressive agents or anti-tumor allies","volume":"24","author":"Anvar","year":"2024","journal-title":"Cancer Cell Int"},{"key":"B24","doi-asserted-by":"publisher","first-page":"8797683","DOI":"10.1155\/2020\/8797683","article-title":"Th17 cells and IL-17 as novel immune targets in ovarian cancer therapy","volume":"2020","author":"Bilska","year":"2020","journal-title":"J Oncol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"13684","DOI":"10.3390\/ijms241813684","article-title":"High tumor-infiltrating lymphocyte count is associated with distinct gene expression profile and longer patient survival in advanced ovarian cancer","volume":"24","author":"Barna","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2021.09.007","article-title":"B cells and cancer","volume":"39","author":"Engelhard","year":"2021","journal-title":"Cancer Cell"},{"key":"B27","doi-asserted-by":"publisher","first-page":"iqae012","DOI":"10.1093\/oxfimm\/iqae012","article-title":"The current understanding of the phenotypic and functional properties of human regulatory B cells (Bregs)","volume":"5","author":"Ahsan","year":"2024","journal-title":"Oxf Open Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-03144-0","article-title":"IgA transcytosis and antigen recognition govern ovarian cancer immunity","volume":"591","author":"Biswas","year":"2021","journal-title":"Nature"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.157215","article-title":"CXCL13-producing CD4+ T cells accumulate in the early phase of tertiary lymphoid structures in ovarian cancer","volume":"7","author":"Ukita","year":"2022","journal-title":"JCI Insight"},{"key":"B30","doi-asserted-by":"publisher","first-page":"101092","DOI":"10.1016\/j.xcrm.2023.101092","article-title":"Tumor and local lymphoid tissue interaction determines prognosis in high-grade serous ovarian cancer","volume":"4","author":"Lu","year":"2023","journal-title":"Cell Rep Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1595070","article-title":"Roles and functions of tumor-infiltrating lymphocytes and tertiary lymphoid structures in gastric cancer progression","volume":"16","author":"Yao","year":"2025","journal-title":"Front Immunol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s12943-024-01980-6","article-title":"Tertiary lymphoid structural heterogeneity determines tumour immunity and prospects for clinical application","volume":"23","author":"Zhang","year":"2024","journal-title":"Mol Cancer"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01869","article-title":"Natural killer cells: development, maturation, and clinical utilization","volume":"9","author":"Abel","year":"2018","journal-title":"Front Immunol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.2001095","article-title":"Ovarian cancer ascites inhibits transcriptional activation of NK cells partly through CA125","volume":"208","author":"Fraser","year":"2022","journal-title":"J Immunol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01782","article-title":"Naturally killing the silent killer: NK cell-based immunotherapy for ovarian cancer","volume":"10","author":"Nersesian","year":"2019","journal-title":"Front Immunol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1146\/annurev-immunol-101921-044122","article-title":"Designing cancer immunotherapies that engage T cells and NK cells","volume":"41","author":"Kyrysyuk","year":"2023","journal-title":"Annu Rev Immunol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-23-1451","article-title":"Iron chelation therapy elicits innate immune control of metastatic ovarian cancer","volume":"14","author":"Sandoval","year":"2024","journal-title":"Cancer Discov"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2023.10.007","article-title":"Tumor macrophage functional heterogeneity can inform the development of novel cancer therapies","volume":"44","author":"Nasir","year":"2023","journal-title":"Trends Immunol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1186\/s12967-025-06643-8","article-title":"Unraveling the role of M2 TAMs in ovarian cancer dynamics: a systematic review","volume":"23","author":"Wang","year":"2025","journal-title":"J Transl Med"},{"key":"B40","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/s41698-024-00522-z","article-title":"Targeting M2-like tumor-associated macrophages is a potential therapeutic approach to overcome antitumor drug resistance","volume":"8","author":"Wang","year":"2024","journal-title":"NPJ Precis Oncol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00691","article-title":"Clinical relevance and immunosuppressive pattern of circulating and infiltrating subsets of myeloid-derived suppressor cells (MDSCs) in epithelial ovarian cancer","volume":"10","author":"Ok\u0142a","year":"2019","journal-title":"Front Immunol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-101819-025146","article-title":"Dendritic cell regulation of T helper cells","volume":"39","author":"Yin","year":"2021","journal-title":"Annu Rev Immunol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-023-00990-6","article-title":"Dendritic cell subsets in cancer immunity and tumor antigen sensing","volume":"20","author":"Del Prete","year":"2023","journal-title":"Cell Mol Immunol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.5MR1216-508R","article-title":"Neutrophils as active regulators of the immune system in the tumor microenvironment","volume":"102","author":"Shaul","year":"2017","journal-title":"J Leukoc Biol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"2411070","DOI":"10.1080\/2162402X.2024.2411070","article-title":"High-grade serous ovarian cancer development and anti-PD-1 resistance is driven by IRE1\u03b1 activity in neutrophils","volume":"13","author":"Emmanuelli","year":"2024","journal-title":"Oncoimmunology"},{"key":"B46","doi-asserted-by":"publisher","first-page":"100146","DOI":"10.1016\/j.cellin.2024.100146","article-title":"PD-1-mediated inhibition of T-cell activation: Mechanisms and strategies for cancer combination immunotherapy","volume":"3","author":"Liu","year":"2024","journal-title":"Cell Insight"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.5603\/GP.a2021.0080","article-title":"The relation of CD3, CD4, CD8 and PD-1 expression with tumor type and prognosis in epithelial ovarian cancers","volume":"92","author":"Arman Karakaya","year":"2021","journal-title":"Ginekol Pol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000001503","article-title":"PD-L1 expression and CD8+ Tumor-infiltrating lymphocytes in different types of tubo-ovarian carcinoma and their prognostic value in high-grade serous carcinoma","volume":"44","author":"Chen","year":"2020","journal-title":"Am J Surg Pathol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.ygyno.2016.03.008","article-title":"PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer","volume":"141","author":"Webb","year":"2016","journal-title":"Gynecol Oncol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1234894\/full","article-title":"Prognostic role of different PD-L1 expression patterns and tumor-infiltrating lymphocytes in high-grade serous ovarian cancer: a systematic review and meta-analysis","volume":"14","author":"Wang","year":"2023","journal-title":"Front Immunol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1097\/PAP.0000000000000161","article-title":"Assessing tumor-infiltrating lymphocytes in solid tumors: A practical review for pathologists and proposal for a standardized method from the international immuno-oncology biomarkers working group: part 2: TILs in melanoma, gastrointestinal tract carcinomas, non-small cell lung carcinoma and mesothelioma, endometrial and ovarian carcinomas, squamous cell carcinoma of the head and neck, genitourinary carcinomas, and primary brain tumors","volume":"24","author":"Hendry","year":"2017","journal-title":"Adv Anat Pathol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/s41573-018-0007-y","article-title":"Approaches to treat immune hot, altered and cold tumours with combination immunotherapies","volume":"18","author":"Galon","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-022-00503-z","article-title":"Immunobiology of high-grade serous ovarian cancer: lessons for clinical translation","volume":"22","author":"Kandalaft","year":"2022","journal-title":"Nat Rev Cancer"},{"key":"B54","doi-asserted-by":"publisher","first-page":"1568\u201386.e10","DOI":"10.1016\/j.ccell.2025.07.005","article-title":"Myeloid cell networks govern re-establishment of original immune landscapes in recurrent ovarian cancer","volume":"43","author":"Ghisoni","year":"2025","journal-title":"Cancer Cell"},{"key":"B55","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s13045-025-01735-w","article-title":"Immunosenescence and cancer: molecular hallmarks, tumor microenvironment remodeling, and age-specific immunotherapy challenges","volume":"18","author":"Liu","year":"2025","journal-title":"J Hematol Oncol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.16429","article-title":"Pretreatment neutrophil-to-lymphocyte ratio: A prognostic biomarker of survival in patients with epithelial ovarian cancer","volume":"13","author":"John-Olabode","year":"2021","journal-title":"Cureus"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1568825","article-title":"Neutrophil-to-lymphocyte ratio predicts a poor prognosis for penile cancer with an immunosuppressive tumor microenvironment","volume":"16","author":"Tan","year":"2025","journal-title":"Front Immunol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"895","DOI":"10.2147\/JIR.S503479","article-title":"Inflammation and immune escape in ovarian cancer: pathways and therapeutic opportunities","volume":"18","author":"Liu","year":"2025","journal-title":"J Inflammation Res"},{"key":"B59","doi-asserted-by":"publisher","first-page":"100856","DOI":"10.1016\/j.xcrm.2022.100856","article-title":"Spatial heterogeneity of infiltrating T cells in high-grade serous ovarian cancer revealed by multi-omics analysis","volume":"3","author":"Yang","year":"2022","journal-title":"Cell Rep Med"},{"key":"B60","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1038\/s41698-025-00973-y","article-title":"A temporal model of tumor-immune dynamics during the metastatic progression of high-grade serous ovarian cancer","volume":"9","author":"Egan","year":"2025","journal-title":"NPJ Precis Oncol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-023-03512-x","article-title":"Discordance of PD-L1 expression in primary and metastatic ovarian high-grade serous carcinoma and its correlation with CD8\u2009+\u2009tumor-infiltrating lymphocytes and patient prognosis","volume":"482","author":"Zhang","year":"2023","journal-title":"Virchows Arch"},{"key":"B62","doi-asserted-by":"publisher","first-page":"6400","DOI":"10.1038\/s41598-021-85966-0","article-title":"PD-1 and PD-L1 expression on TILs in peritoneal metastases compared to ovarian tumor tissues and its associations with clinical outcome","volume":"11","author":"Bekos","year":"2021","journal-title":"Sci Rep"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-05496-1","article-title":"Ovarian cancer mutational processes drive site-specific immune evasion","volume":"612","author":"V\u00e1zquez-Garc\u00eda","year":"2022","journal-title":"Nature"},{"key":"B64","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.immuni.2020.12.001","article-title":"The persistence of interleukin-6 is regulated by a blood buffer system derived from dendritic cells","volume":"54","author":"Yousif","year":"2021","journal-title":"Immunity"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.7277","article-title":"Association and prognostic significance of BRCA1\/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1\/PD-L1 in high grade serous ovarian cancer","volume":"7","author":"Strickland","year":"2016","journal-title":"Oncotarget"},{"key":"B66","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1038\/s41467-022-28389-3","article-title":"Single-cell tumor-immune microenvironment of BRCA1\/2 mutated high-grade serous ovarian cancer","volume":"13","author":"Launonen","year":"2022","journal-title":"Nat Commun"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-009058","article-title":"Unique immune characteristics and differential anti-PD-1-mediated reinvigoration potential of CD8+ TILs based on BRCA1\/2 mutation status in epithelial ovarian cancers","volume":"12","author":"Park","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.173.4.2227","article-title":"Cutting edge: estrogen drives expansion of the CD4+CD25+ regulatory T-cell compartment","volume":"173","author":"Polanczyk","year":"2004","journal-title":"J Immunol"},{"key":"B69","doi-asserted-by":"publisher","first-page":"103346","DOI":"10.1016\/j.jri.2021.103346","article-title":"Menopause is an inflection point of age-related immune changes in women","volume":"146","author":"Han","year":"2021","journal-title":"J Reprod Immunol"},{"key":"B70","doi-asserted-by":"publisher","first-page":"5714","DOI":"10.3390\/ijms22115714","article-title":"Clinical significance of tumor infiltrating lymphocytes in association with hormone receptor expression patterns in epithelial ovarian cancer","volume":"22","author":"Han","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B71","doi-asserted-by":"publisher","first-page":"bqac098","DOI":"10.1210\/endocr\/bqac098","article-title":"Regulatory T cell proportion and phenotype are altered in women using oral contraception","volume":"163","author":"Moldenhauer","year":"2022","journal-title":"Endocrinology"},{"key":"B72","doi-asserted-by":"publisher","first-page":"5578","DOI":"10.3390\/cancers13215578","article-title":"Highly expressed progesterone receptor B isoform increases platinum sensitivity and survival of ovarian high-grade serous carcinoma","volume":"13","author":"Lin","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B73","doi-asserted-by":"publisher","first-page":"BSR20210478","DOI":"10.1042\/BSR20210478","article-title":"Expression of hormone receptors predicts survival and platinum sensitivity of high-grade serous ovarian cancer","volume":"41","author":"Tan","year":"2021","journal-title":"Biosci Rep"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000337","article-title":"Consensus guidelines for the definition, detection and interpretation of immunogenic cell death","volume":"8","author":"Galluzzi","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B75","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/s41577-019-0215-7","article-title":"DAMP-sensing receptors in sterile inflammation and inflammatory diseases","volume":"20","author":"Gong","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2021.11.004","article-title":"Enhancing cancer chemo-immunotherapy by biomimetic nanogel with tumor targeting capacity and rapid drug-releasing in tumor microenvironment","volume":"12","author":"Shang","year":"2022","journal-title":"Acta Pharm Sin B"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1200245","article-title":"GAS-STING: a classical DNA recognition pathways to tumor therapy","volume":"14","author":"Wang","year":"2023","journal-title":"Front Immunol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-17-3480","article-title":"Paclitaxel reduces tumor growth by reprogramming tumor-associated macrophages to an M1 profile in a TLR4-dependent manner","volume":"78","author":"Wanderley","year":"2018","journal-title":"Cancer Res"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-14-3098","article-title":"Chemotherapy induces programmed cell death-ligand 1 overexpression via the nuclear factor-\u03baB to foster an immunosuppressive tumor microenvironment in ovarian cancer","volume":"75","author":"Peng","year":"2015","journal-title":"Cancer Res"},{"key":"B80","doi-asserted-by":"publisher","first-page":"101076","DOI":"10.1016\/j.tranon.2021.101076","article-title":"Type of chemotherapy has substantial effects on the immune system in ovarian cancer","volume":"14","author":"Vankerckhoven","year":"2021","journal-title":"Transl Oncol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-3836","article-title":"Spatial profiling of ovarian carcinoma and tumor microenvironment evolution under neoadjuvant chemotherapy","volume":"30","author":"Yaniz-Galende","year":"2024","journal-title":"Clin Cancer Res"},{"key":"B82","doi-asserted-by":"publisher","first-page":"e943170","DOI":"10.12659\/MSM.943170","article-title":"Prognostic impact of tumor-infiltrating immune cells on efficacy of neoadjuvant chemotherapy in patients with advanced or metastatic ovarian cancer: A retrospective study","volume":"30","author":"Rao","year":"2024","journal-title":"Med Sci Monitor : Int Med J Exp Clin Res"},{"key":"B83","doi-asserted-by":"publisher","first-page":"10144","DOI":"10.1038\/s41467-024-54295-x","article-title":"Immunotherapy that improves response to chemotherapy in high-grade serous ovarian cancer","volume":"15","author":"Elorbany","year":"2024","journal-title":"Nat Commun"},{"key":"B84","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1186\/s13048-024-01533-x","article-title":"The predictive role of PD-L1 expression and CD8\u2009+\u2009TIL levels in determining the neoadjuvant chemotherapy response in advanced ovarian cancer","volume":"17","author":"Aliyeva","year":"2024","journal-title":"J Ovarian Res"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1022942","article-title":"Tumor immune microenvironment changes are associated with response to neoadjuvant chemotherapy and long-term survival benefits in advanced epithelial ovarian cancer: A pilot study","volume":"14","author":"Cao","year":"2023","journal-title":"Front Immunol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.e17605","article-title":"The tumor immune microenvironment correlates with neoadjuvant chemotherapy response in high-grade serous ovarian cancer","volume":"40","author":"Zhu","year":"2022","journal-title":"JCO"},{"key":"B87","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/s41389-022-00419-1","article-title":"The impact of neoadjuvant chemotherapy on the tumor microenvironment in advanced high-grade serous carcinoma","volume":"11","author":"Shen","year":"2022","journal-title":"Oncogenesis"},{"key":"B88","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.3390\/cancers14092308","article-title":"Dynamics of the tumor immune microenvironment during neoadjuvant chemotherapy of high-grade serous ovarian cancer","volume":"14","author":"Lee","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-020-02670-0","article-title":"Neoadjuvant chemotherapy alters the balance of effector to suppressor immune cells in advanced ovarian cancer","volume":"70","author":"Leary","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2020.09.045","article-title":"Distribution of novel immune-checkpoint targets in ovarian cancer tumor microenvironment: A dynamic landscape","volume":"160","author":"Blanc-Durand","year":"2021","journal-title":"Gynecol Oncol"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1111\/apm.13116","article-title":"Immunotyping in tubo-ovarian high-grade serous carcinoma by PD-L1 and CD8+ T-lymphocytes predicts disease-free survival","volume":"129","author":"Bansal","year":"2021","journal-title":"APMIS"},{"key":"B92","doi-asserted-by":"publisher","first-page":"1760705","DOI":"10.1080\/2162402X.2020.1760705","article-title":"Deep immune profiling of ovarian tumors identifies minimal MHC-I expression after neoadjuvant chemotherapy as negatively associated with T cell-dependent outcome","volume":"9","author":"Brunekreeft","year":"2020","journal-title":"Oncoimmunology"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-2657","article-title":"Neoadjuvant chemotherapy modulates the immune microenvironment in metastases of tubo-ovarian high-grade serous carcinoma","volume":"22","author":"B\u00f6hm","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw625","article-title":"Neoadjuvant chemotherapy (NACT) increases immune infiltration and programmed death-ligand 1 (PD-L1) expression in epithelial ovarian cancer (EOC)","volume":"28","author":"Mesnage","year":"2017","journal-title":"Ann Oncol"},{"key":"B95","doi-asserted-by":"publisher","first-page":"3580","DOI":"10.3390\/cancers16213580","article-title":"Molecular alterations in paired epithelial ovarian tumors in patients treated with neoadjuvant chemotherapy","volume":"16","author":"Nikolaidi","year":"2024","journal-title":"Cancers"},{"key":"B96","doi-asserted-by":"publisher","first-page":"48","DOI":"10.21776\/ub.crjim.2025.006.01.08","article-title":"Analysis of the impact of neoadjuvant chemotherapy on CD8+ Tumour infil-trating lymphocytes in epithelial ovarian cancer","volume":"6","author":"Thangam","year":"2025","journal-title":"Clin Res J Internal Med"},{"key":"B97","doi-asserted-by":"publisher","first-page":"105133","DOI":"10.1016\/j.esmoop.2025.105133","article-title":"4P T-cell phenotype and repertoire are modulated by neoadjuvant chemotherapy (NACT) in high-grade serous ovarian cancer (HGSOC)","volume":"10","author":"Marin Jimenez","year":"2025","journal-title":"ESMO Open"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-2834","article-title":"Improved T cell immunity following neoadjuvant chemotherapy in ovarian cancer","volume":"28","author":"Liu","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B99","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1016\/j.ccell.2024.11.005","article-title":"Chemotherapy induces myeloid-driven spatially confined T cell exhaustion in ovarian cancer","volume":"42","author":"Launonen","year":"2024","journal-title":"Cancer Cell"},{"key":"B100","doi-asserted-by":"publisher","first-page":"5647","DOI":"10.3390\/cancers14225647","article-title":"Longitudinal modulation of loco-regional immunity in ovarian cancer patients receiving intraperitoneal chemotherapy","volume":"14","author":"Suarez Mora","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-020-0630-5","article-title":"Unraveling tumor-immune heterogeneity in advanced ovarian cancer uncovers immunogenic effect of chemotherapy","volume":"52","author":"Jim\u00e9nez-S\u00e1nchez","year":"2020","journal-title":"Nat Genet"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-20-0968","article-title":"Chemotherapy induces tumor-associated macrophages that aid adaptive immune responses in ovarian cancer","volume":"9","author":"Heath","year":"2021","journal-title":"Cancer Immunol Res"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-1594","article-title":"Chemotherapy drives tertiary lymphoid structures that correlate with ICI-responsive TCF1+CD8+ T cells in metastatic ovarian cancer","volume":"31","author":"Lanickova","year":"2025","journal-title":"Clin Cancer Res"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1016\/j.pathol.2020.10.007","article-title":"Programmed death ligand-1 (PD-L1) as a predictive marker for immunotherapy in solid tumours: a guide to immunohistochemistry implementation and interpretation","volume":"53","author":"Paver","year":"2021","journal-title":"Pathology"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-3753","article-title":"Neoadjuvant chemotherapy with dual immune checkpoint inhibitors for advanced-stage ovarian cancer: final analysis of TRU-D phase II nonrandomized clinical trial","volume":"31","author":"Park","year":"2025","journal-title":"Clin Cancer Res"},{"key":"B106","doi-asserted-by":"publisher","first-page":"5931","DOI":"10.1038\/s41467-024-46999-x","article-title":"Neoadjuvant and adjuvant pembrolizumab in advanced high-grade serous carcinoma: the randomized phase II NeoPembrOV clinical trial","volume":"15","author":"Ray-Coquard","year":"2024","journal-title":"Nat Commun"},{"key":"B107","doi-asserted-by":"publisher","first-page":"S1397","DOI":"10.1016\/j.annonc.2022.08.026","article-title":"LBA30 Phase III ATALANTE\/ov29 trial: Atezolizumab (Atz) versus placebo with platinum-based chemotherapy (Cx) plus bevacizumab (bev) in patients (pts) with platinum-sensitive relapse (PSR) of epithelial ovarian cancer (OC)","volume":"33","author":"Kurtz","year":"2022","journal-title":"Ann Oncol"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00216-3","article-title":"Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study","volume":"22","author":"Pujade-Lauraine","year":"2021","journal-title":"Lancet Oncol"},{"key":"B109","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1001\/jamaoncol.2020.5945","article-title":"Efficacy and safety of pembrolizumab in combination with bevacizumab and oral metronomic cyclophosphamide in the treatment of recurrent ovarian cancer: A phase 2 nonrandomized clinical trial","volume":"7","author":"Zsiros","year":"2021","journal-title":"JAMA Oncol"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2020.07.028","article-title":"Combined pembrolizumab and pegylated liposomal doxorubicin in platinum resistant ovarian cancer: A phase 2 clinical trial","volume":"159","author":"Lee","year":"2020","journal-title":"Gynecol Oncol"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003122","article-title":"Pembrolizumab with low-dose carboplatin for recurrent platinum-resistant ovarian, fallopian tube, and primary peritoneal cancer: survival and immune correlates","volume":"9","author":"Liao","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-0507","article-title":"Intraperitoneal nivolumab after debulking surgery and hyperthermic intraperitoneal chemotherapy in advanced ovarian cancer: A phase I study with expansion cohort","volume":"30","author":"Corbaux","year":"2024","journal-title":"Clin Cancer Res"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2025.04.578","article-title":"OVATION-2: A randomized phase I\/II study evaluating the safety and efficacy of IMNN-001 (IL-12 gene therapy) with neo\/adjuvant chemotherapy in patients newly-diagnosed with advanced epithelial ovarian cancer","volume":"197","author":"Thaker","year":"2025","journal-title":"Gynecologic Oncol"},{"key":"B114","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.ygyno.2023.12.029","article-title":"Durvalumab with or without tremelimumab plus chemotherapy in HRR non-mutated, platinum-resistant ovarian cancer (KGOG 3045): A phase II umbrella trial","volume":"182","author":"Kim","year":"2024","journal-title":"Gynecol Oncol"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00529","article-title":"Atezolizumab combined with bevacizumab and platinum-based therapy for platinum-sensitive ovarian cancer: placebo-controlled randomized phase III ATALANTE\/ENGOT-ov29 trial","volume":"41","author":"Kurtz","year":"2023","journal-title":"J Clin Oncol"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.10.031","article-title":"LBA37 Atezolizumab (atezo) combined with platinum-based chemotherapy (CT) and maintenance niraparib for recurrent ovarian cancer (rOC) with a platinum-free interval (TFIp) >6 months: Primary analysis of the double-blind placebo (pbo)-controlled ENGOT-Ov41\/GEICO 69-O\/ANITA phase III trial","volume":"34","author":"Gonzalez Martin","year":"2023","journal-title":"Ann Oncol"},{"key":"B117","doi-asserted-by":"publisher","first-page":"100494","DOI":"10.1016\/j.medj.2024.07.022","article-title":"Pembrolizumab plus chemotherapy in frontline treatment of advanced ovarian cancer: Clinical and translational results from a phase 2 trial","volume":"6","author":"How","year":"2025","journal-title":"Med"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007697","article-title":"Timed adoptive T-cell transfer during chemotherapy in patients with recurrent platinum-sensitive epithelial ovarian cancer","volume":"11","author":"Verdegaal","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003190","article-title":"Safety and efficacy of dendritic cell-based immunotherapy DCVAC\/OvCa added to first-line chemotherapy (carboplatin plus paclitaxel) for epithelial ovarian cancer: a phase 2, open-label, multicenter, randomized trial","volume":"10","author":"Rob","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B120","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s12943-024-02208-3","article-title":"Myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment and their targeting in cancer therapy","volume":"24","author":"He","year":"2025","journal-title":"Mol Cancer"},{"key":"B121","doi-asserted-by":"publisher","first-page":"vdad088","DOI":"10.1093\/noajnl\/vdad088","article-title":"A pilot phase Ib study to evaluate tadalafil to overcome immunosuppression during chemoradiotherapy for IDH-wild-type glioblastoma","volume":"5","author":"Ghosh","year":"2023","journal-title":"Neurooncol Adv"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1093\/jimmun\/vkaf036","article-title":"Natural killer cell\u2013based immunotherapy for cancer","volume":"214","author":"Ma","year":"2025","journal-title":"J Immunol"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.613773","article-title":"Dendritic cell vaccines in ovarian cancer","volume":"11","author":"Zhang","year":"2020","journal-title":"Front Immunol"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1007\/s13402-014-0207-3","article-title":"Apoptosis induction by an analog of curcumin (BDMC-A) in human laryngeal carcinoma cells through intrinsic and extrinsic pathways","volume":"37","author":"Mohankumar","year":"2014","journal-title":"Cell Oncol (Dordr)"},{"key":"B125","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.cbi.2013.12.006","article-title":"Mechanism of apoptotic induction in human breast cancer cell, MCF-7, by an analog of curcumin in comparison with curcumin\u2013an in vitro and in silico approach","volume":"210","author":"Mohankumar","year":"2014","journal-title":"Chem Biol Interact"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2015.07.024","article-title":"BDMC-A, an analog of curcumin, inhibits markers of invasion, angiogenesis, and metastasis in breast cancer cells via NF-\u03baB pathway\u2013A comparative study with curcumin","volume":"74","author":"Mohankumar","year":"2015","journal-title":"BioMed Pharmacother"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.4103\/0973-1296.203981","article-title":"In vitro Anti-Proliferative Effect of Tephrosia purpurea on Human Hepatocellular Carcinoma Cells","volume":"13","author":"Padmapriya","year":"2017","journal-title":"Pharmacogn Mag"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.26047","article-title":"T11TS immunotherapy repairs PI3K-AKT signaling in T cells: Clues toward enhanced T cell survival in rat glioma model","volume":"233","author":"Chaudhuri","year":"2018","journal-title":"J Cell Physiol"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2015.06.002","article-title":"Disease relevance of T11TS-induced T cell signal transduction through the CD2-mediated calcineurin-NFAT pathway: Perspectives in glioma immunotherapy","volume":"67","author":"Chaudhuri","year":"2015","journal-title":"Mol Immunol"},{"key":"B130","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1186\/s12967-024-05826-z","article-title":"Clinical trial landscape for TIL therapy: emerging insights and future directions in oncology","volume":"22","author":"Hong","year":"2024","journal-title":"J Transl Med"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-2428","article-title":"TIL therapy: facts and hopes","volume":"29","author":"Monberg","year":"2023","journal-title":"Clin Cancer Res"},{"key":"B132","doi-asserted-by":"publisher","first-page":"17588359211008399","DOI":"10.1177\/17588359211008399","article-title":"Cell therapies in ovarian cancer","volume":"13","author":"Sarivalasis","year":"2021","journal-title":"Ther Adv Med Oncol"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2024.06.015","article-title":"Tumor-infiltrating lymphocytes: A new hope","volume":"42","author":"Sarnaik","year":"2024","journal-title":"Cancer Cell"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1302307","article-title":"CAR-T-cell immunotherapy for ovarian cancer: hushing the silent killer","volume":"14","author":"Nasiri","year":"2023","journal-title":"Front Immunol"},{"key":"B135","doi-asserted-by":"publisher","first-page":"116349","DOI":"10.1016\/j.bcp.2024.116349","article-title":"CAR-T therapy for ovarian cancer: Recent advances and future directions","volume":"226","author":"Xin","year":"2024","journal-title":"Biochem Pharmacol"},{"key":"B136","doi-asserted-by":"publisher","first-page":"819","DOI":"10.3390\/diagnostics14080819","article-title":"CAR-T cell therapy in ovarian cancer: where are we now","volume":"14","author":"Cutri-French","year":"2024","journal-title":"Diagnostics (Basel)"},{"key":"B137","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1186\/s13048-025-01831-y","article-title":"T cell receptor therapy in ovarian cancer: concepts and challenges","volume":"18","author":"Wang","year":"2025","journal-title":"J Ovarian Res"},{"key":"B138","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s13048-020-00667-y","article-title":"Differences in immune-related gene expressions and tumor-infiltrating lymphocytes according to chemotherapeutic response in ovarian high-grade serous carcinoma","volume":"13","author":"Choi","year":"2020","journal-title":"J Ovarian Res"},{"key":"B139","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s40164-024-00543-1","article-title":"Tumor battlefield within inflamed, excluded or desert immune phenotypes: the mechanisms and strategies","volume":"13","author":"Zheng","year":"2024","journal-title":"Exp Hematol Oncol"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2021-003116","article-title":"BRCA status and platinum sensitivity in advanced ovarian cancer according to Chemotherapy Response Score","volume":"32","author":"Ergasti","year":"2022","journal-title":"Int J Gynecol Cancer"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1601773","article-title":"Tumor-infiltrating lymphocytes in cancer immunotherapy: from chemotactic recruitment to translational modeling","volume":"16","author":"Kraja","year":"2025","journal-title":"Front Immunol"},{"key":"B142","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ygyno.2024.01.032","article-title":"The emerging and challenging role of PD-L1 in patients with gynecological cancers: An updating review with clinico-pathological considerations","volume":"184","author":"Santoro","year":"2024","journal-title":"Gynecol Oncol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1757366\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T06:41:28Z","timestamp":1771483288000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1757366\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,19]]},"references-count":142,"alternative-id":["10.3389\/fimmu.2026.1757366"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1757366","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,19]]},"article-number":"1757366"}}